← ANALYST RATINGS · TIPRANKS
enGene Holdings (ENGN): analyst forecast and price target
Analyst consensus
Hold1 Buy4 Hold1 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $2.80, the highest $4.00, the lowest $2.00. The average is +67.7% from the last price of $1.67.
Analyst ratings 11
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $4.00 | Hold | +139.5% | Reiterated | 16.10.26on TipRanks 07:35 | −1.2% | ↗ |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $4.00 | Buy | +139.5% | Reiterated | 16.10.26on TipRanks 06:35 | −1.2% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 → $1.50−25.0% | Hold | −10.2% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 → $1.50−25.0% | Hold | −10.2% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 → $1.50−25.0% | Hold | −10.2% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 → $1.50−25.0% | Sell | −10.2% | Downgrade | 15.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 → $1.50−25.0% | Hold | −10.2% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $1.50−25.0% | Hold | −10.2% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $2.00 | Hold | +19.8% | Reiterated | 02.10.26on TipRanks Oct 5 07:36 | −2.8%next day −4.3% · 5 days −12.0% | ↗ |
| David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% | UBS | $2.00 | Hold | +19.8% | Assigned | 16.09.26on TipRanks 07:55 | +1.5%next day −1.1% · 5 days +2.6% | ↗ |
| Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% | Leerink Partners | $2.00 | Hold | +19.8% | Reiterated | 09.09.26on TipRanks 08:35 | −3.2%next day −3.7% · 5 days +4.3% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | — | Sell | — | Reiterated | 12.08.26on TipRanks 09:25 | −6.8%next day −1.3% · 5 days +9.3% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | — | Hold | — | Reiterated | 16.06.26on TipRanks 06:55 | −0.5%next day +0.7% · 5 days +2.0% | ↗ |
| Sean McCutcheon★★★★★★★★★★#1382 · hits 43% · avg +39.7% | Raymond James | $27.00 → $4.00−85.2% | Buy | +139.5% | Reiterated | 08.05.26on TipRanks 05:20 | −13.6%next day −0.9% · 5 days +14.5% | ↗ |
| Silvan Tuerkcan★★★★★★★★★★#731 · hits 43% · avg +16.6% | Citizens JMP | — | Hold | — | Downgrade | 08.05.26on TipRanks 05:05 | −13.6%next day −0.9% · 5 days +14.5% | ↗ |
| Xin Yang NG | USmart Securities | $21.50 | Buy | +1,187.4% | Initiated | 13.04.26on TipRanks 23:30 | +1.1%next day +1.3% · 5 days +10.6% | ↗ |
| Maury Raycroft★★★★★★★★★★#1326 · hits 44% · avg +12.0% | Jefferies | $28.00 | Buy | +1,576.6% | Reiterated | 25.02.26on TipRanks 10:55 | +2.4%next day −0.1% · 5 days −2.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering enGene Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 7 | 4 | 2 | 2 | 3 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 9 | 11 | 11 | 4 | 3 | 5 |
| Sell | 0 | 1 | 1 | 2 | 1 | 1 |
Earnings and sales forecast
Next report: 23.12.26 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.46 (from $-0.55 to $-0.37). Last quarter: $-0.47.
Best top-analyst consensus in the sector · Healthcare
About enGene Holdings
- CEO: Ronald H. W. Cooper
- Employees: 82
- 4868 Rue Levy, Montreal, QC, H4R 2P1, CA
- www.engene.com
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Data from the stock’s TipRanks forecast page, read 64 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗